A61K - Preparations for medical, dental, or toilet purposes

More topics under "A61K - Preparations for medical, dental, or toilet purposes" (2,585,043)
A61K 101 - Radioactive non-metals (526)
A61K 103 - Radioactive metals (481)
A61K 125 - Containing or obtained from roots, bulbs, tubers, corms or rhizomes (2,645)
A61K 127 - Containing or obtained from leaves (1,806)
A61K 129 - Containing or obtained from bark (325)
A61K 131 - Containing or obtained from seeds, nuts, fruits or grains (1,932)
A61K 133 - Containing or obtained from flowers or blossoms (665)
A61K 135 - Containing or obtained from stems, stalks, branches, twigs or shoots (756)
A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
A61K 33 - Medicinal preparations containing inorganic active ingredients (56,213)
A61K 35 - Medicinal preparations containing material or reaction products thereof with undetermined constitution (125,838)
A61K 36 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines (179,316)
A61K 38 - Medicinal preparations containing peptides (316,240)
A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
A61K 41 - Medicinal preparations obtained by treating materials with wave energy or particle radiation (9,445)
A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
A61K 49 - Preparations for testing in vivo (35,376)
A61K 50 - Electrically conductive preparations for use in therapy or testing in vivo, e.g. conductive adhesives or gels to be used with electrodes for electrocardiography (ecg) or for transcutaneous drug administration (62)
A61K 51 - Preparations containing radioactive substances for use in therapy or testing in vivo (24,291)
A61K 6 - Preparations for dentistry (18,259)
A61K 8 - Cosmetics or similar toilet preparations (170,551)
A61K 9 - Medicinal preparations characterised by special physical form (299,044)

Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449)
11/2004
11/04/2004	WO2004093782A2 Tumor cytotoxicity induced by modulators of the cxcr4 receptor
11/04/2004	WO2004093781A2 Podophyllotoxin derivatives as igf-1r inhibitors
11/04/2004	WO2004093780A2 Process for the preparation of gabapentin form-ii
11/04/2004	WO2004093779A2 Process for the preparation of gabapentin form-ii
11/04/2004	WO2004093778A2 Oligonucleotides that block toll-like receptors
11/04/2004	WO2004084808A3 Animal with surgically modified gastrointestinal tract and method for study of weight reduction
11/04/2004	WO2004082589A3 Nasally administrable, bioavailable pharmaceutical composition of loratadine
11/04/2004	WO2004082577A3 8-SUBSTITUTED-6, 7, 8, 9-TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE DERIVATIVES
11/04/2004	WO2004073600A3 A novel process and appratus for the manufacture of precipitated silica from rice husk ash
11/04/2004	WO2004071463A3 Fluoromethotrexates and uses therefor
11/04/2004	WO2004069194A3 Use of the oxidoreductase ncb50r for diagnosings and treating diabetes
11/04/2004	WO2004064786A3 Article for debridement and detoxification of wounds
11/04/2004	WO2004064744A3 Methods for site-directed mutagenesis and targeted randomization
11/04/2004	WO2004064713A3 The use of yop preoteins or rho gtpase inhibitors as caspase-1 inhibitors
11/04/2004	WO2004062613A3 Hiv integrase inhibitors
11/04/2004	WO2004062600A3 Antiviral patch
11/04/2004	WO2004062596A3 Antineoplastic ether lipid compounds having a four carbon backbone
11/04/2004	WO2004062584A3 Therapeutic and prophylactic vaccine for the treatment and prevention of papillomavirus infection
11/04/2004	WO2004061084A3 Modulation of protein functionalities
11/04/2004	WO2004060267A3 A process for producing enriched fractions containing up to 100% of bacoside a and bacoside b
11/04/2004	WO2004058142A3 Improved combine vaccine against mycoplasma hyopneumoniae and porcine viruses
11/04/2004	WO2004047514A3 Methods for identifying risk of breast cancer and treatments thereof
11/04/2004	WO2004045549A3 Medical devices employing novel polymers
11/04/2004	WO2004043340A3 Alpha 5 beta 1 and its ability to regulate the cell survival pathway
11/04/2004	WO2004037167A3 Methods of treating dry eye disease with lantibiotics
11/04/2004	WO2004035008A3 Treatment of infections and other disorders
11/04/2004	WO2004035007A3 Transmucosal administration of aggregated antigens
11/04/2004	WO2004034996A3 TREATING ALCOHOL AND OR SUBSTANCE ABUSE BY ANTAGONIZING α 2 ADRENERGIC RECEPTORS WITH WEAK DOPAMINE BLOCKING
11/04/2004	WO2004022003A3 Materials and methods for treatment of allergic diseases
11/04/2004	WO2004009035A3 Compositions and products containing enantiomeric equol, and methods for their making
11/04/2004	US20040220264 Bioavailability and improved delivery of acidic pharmaceutical drugs
11/04/2004	US20040220251 Furanose-type bicyclic carbohydrates with biological activity
11/04/2004	US20040220233 for treating p38 kinase-associated conditions; may be useful in treating inflammatory bowel disease, rheumatoid arthritis, psoriasis, multiple sclerosis, endotoxin shock, osteoporosis, Alzheimer's disease, and congestive heart failure
11/04/2004	US20040220209 Novel imidazopyridine compounds with therapeutic effect
11/04/2004	US20040220203 Method and composition for potentiating an opiate analgesic
11/04/2004	US20040220184 Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD)
11/04/2004	US20040220162 Compounds useful in the manufacture of an anti-inflammatory androstane derivative
11/04/2004	US20040220157 a 3-oxoandrostrane carbothioic acid compound
11/04/2004	US20040219684 In vitro prediction of sunscreen PFA values
11/04/2004	US20040219602 Evaluating effects of exposure conditions on drug samples over time
11/04/2004	US20040219579 Identifying nucleic acid and protein expression profiles associated with cell proliferative and metabolic disorders; cancer associated proteins/transcripts and high throughput screening
11/04/2004	US20040219575 Using presence of transcription factor/tumor antigen splice variant to diagnose cell proliferative disorders; tumor cell characterization
11/04/2004	US20040219240 hops extracts or derivatives, in combination with an analgesic compound and/or an anti-inflammatory compound for reducing gastroenteropathy or gastric toxicity, including ulcerogenic-type disorders
11/04/2004	US20040219203 Anti-CD74 immunoconjugates and methods
11/04/2004	US20040219174 Contraception process and administration form for the same
11/04/2004	US20040219147 administering an anti-inflammatory compound, especially an antibody to a complement component or an NSAID, to a subject receiving a stent in connection with percutaneous transluminal coronary angioplasty.
11/04/2004	US20040219145 Compositions and methods to modulate immune and inflammatory responses
11/04/2004	US20040219142 Treatment of skin and nail disorders using TNFalpha inhibitors
11/04/2004	US20040219133 cells are dispersed using an air-jet sprayer after being suspended in a soluble media either directly onto the area or onto a tissue scaffold to form three dimensional epithelial tissue
11/04/2004	US20040219096 Enhancing interferon gamma production using interleukin 27; treating immune and proliferative disorders
11/04/2004	CA2559330A1 Apparatus and methods for repetitive microjet drug delivery
11/04/2004	CA2523197A1 Peptide vectors
11/04/2004	CA2522946A1 Selective spirocyclic glucocorticoid receptor modulators
11/04/2004	CA2522759A1 Substituted isochroman compounds for the treatment of metabolic disorders, cancer and other diseases
11/04/2004	CA2522662A1 Compositions for delivery of drug combinations
11/04/2004	CA2522497A1 Yeast ectopically expressing abnormally processed proteins and uses therefor
11/04/2004	CA2522359A1 Pathotropic retroviral vector used to deliver diagnostic or therapeutic compositions
11/04/2004	CA2522184A1 Desmoglein 4 is a novel gene involved in hair growth
11/04/2004	CA2522172A1 Rhesus monkey bombesin receptor subtype-3 (brs-3), nucleotides encoding same, and uses thereof
11/04/2004	CA2520424A1 Model for neurodegenerative disorders
11/04/2004	CA2519552A1 Extruded particles containing adverse agents such as opioid antagonists to decrease drug abuse potential
11/04/2004	CA2518336A1 Polyethelene glycol link glp-1 compounds
11/04/2004	CA2517560A1 Thyronamine derivatives and analogs and methods of use thereof
11/04/2004	CA2517134A1 Methods for obtaining colonization factors from bacterial strains
11/03/2004	EP1473294A2 Substituted 1,3-oxathiolanes with antiviral properties
11/03/2004	EP1471870A2 Use of lipid conjugates in the treatment of disease
11/03/2004	EP1337271B1 Combination of gaba agonists and sorbitol dehydrogenase inhibitors
11/03/2004	EP1267892B1 Use of cdp-choline for the treatment of alcohol withdrawal syndrome
11/03/2004	CN1543464A Novel imidazopyridine compounds with therapeutic effect
11/03/2004	CN1541656A Extracts of shark cartilage having an anti-angiogenic activity and an effect on tumor regression; process of making thereof
11/03/2004	CN1173974C Piperidylaminomethyltrifluoromethyl cyclic ether compound as p substance antagonist
11/03/2004	CN1173953C Method for preparing 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline
11/03/2004	CN1173703C Pharmaceutical composition
11/03/2004	CN1173692C Cosmetic composition and method for reducing skin aging procedure
11/02/2004	US6812219 Methods and compositions for treating flaviviruses and pestiviruses
11/02/2004	US6812213 Steroidal sapogenins and their derivatives for treating alzheimer's disease
11/02/2004	US6812021 Isolated from streptococcus; for preparation of therapeutics (vaccines) to immunize against microbial infection; urinary tract infections; drug screening
10/2004
10/28/2004	WO2004092146A2 N- (((((1,3-thiazol-2-yl) amino) carbonyl) phenyl) sulfonyl) phenylalanine derivatives and related compounds for the treatment of diabetes
10/28/2004	WO2004092124A2 Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors
10/28/2004	WO2004091553A2 Film forming polymers, methods of use, and devices and applications thereof
10/28/2004	WO2004091551A2 Anti-tumor vasculature effects of human serum albumin derivatives
10/28/2004	WO2004091550A2 Compositions and methods for delivering thymosin beta 4, analogues, isoforms and other derivatives
10/28/2004	WO2004091549A2 Process for making alpha-substituted hydroxamic acids
10/28/2004	WO2004091548A2 Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods
10/28/2004	WO2004091547A2 Compounds, compositions, and methods
10/28/2004	WO2004091546A2 Central nervous system stimulant and opioid antagonist combinations
10/28/2004	WO2004091543A2 Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
10/28/2004	WO2004091542A2 Nitrogen containing integrin targeting compounds
10/28/2004	WO2004091541A2 Methods for the controlled delivery of pharmacologically active compounds
10/28/2004	WO2004091539A2 Fluid mixing methods and apparatus
10/28/2004	WO2004091538A2 Homogeneous, thermoreversible alginate films and soft capsules made therefrom
10/28/2004	WO2004091537A2 Process for making gel films
10/28/2004	WO2004091536A2 An albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
10/28/2004	WO2004091535A2 Methods of administering estrogens and progestins
10/28/2004	WO2004091534A2 Inhibitors of n ethylmaleimide sensitive factor
10/28/2004	WO2004091533A2 Delivery systems of homogeneous, thermoreversible gel film containing kappa-2 carrageenan
10/28/2004	WO2004091532A2 Homogeneous, thermoreversible gel containing reduced viscosity carrageenan and products made therefrom
10/28/2004	WO2004091530A2 Homogeneous, thermoreversible gel film containing kappa-2 carrageenan and soft capsules made therefrom
10/28/2004	WO2004091529A2 Homogeneous, thermoreversible low viscosity polymannan gum films and soft capsules made therefrom
10/28/2004	WO2004091528A2 Delivery systems of homogeneous thermoreversible alginate films

1 ... 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 ... 295